3. Alimera Sciences (ALIM) is a biopharmaceutical company researches, develops, and commercializes prescription ophthalmic pharmaceuticals.
All the six analysts covering the stock recommend buying. In comparison buy ratings for Allergan (AGN), Regeneron Pharmaceuticals (REGN), Opko Health (OPK), QLT (QLTI), Inspire Pharmaceuticals (ISPH) and ISTA Pharmaceuticals (ISTA) are 70%, 64%, 0%, 75%, 11% and 67%, respectively.
Analysts polled by Bloomberg foresee the stock gaining around 25% over the next 12 months at a consensus target price of $12.7.